A United States Air Force (US Air Force) veteran and private equity leader, Ralph Thurman of Malvern, Pennsylvania, has executed in excess of $2 billion in equity investments, debt transactions, and acquisitions involving life sciences, IT, industrial, and service companies. He has also advised more than a dozen businesses in these sectors through board or chairman positions. The executive chairman of Outlook Therapeutics, Inc., Ralph Thurman also functions as the director of TFF Pharmaceuticals, Inc.
Ralph Thurman previously served as the chairman and CEO of VIASYS Healthcare, Inc., a publicly traded private equity medical technology firm that he founded in 1999. He increased its value fourfold over eight years and sold it for 14.3 times its earnings before interest, taxes, depreciation, and amortization (EBITDA) in 2007. Before he launched VIASYS Healthcare, he served for five years as the board chairman and CEO of Corning Life Sciences, where he expanded global sales from $700 million to in excess of $2 billion.
Ralph Thurman began his career at Rhone-Poulenc Rorer Pharmaceuticals, Inc., and eventually became the president during his nine-year tenure with the company. Prior to this, he was a US Air Force fighter pilot and an instructor for an Air Force advanced fighter pilot training program. An alumnus of the Wharton School at the University of Pennsylvania’s corporate governance program, he has a master of arts in management and an undergraduate in economics from Webster University and Virginia Polytechnic Institute and State University, respectively.
Ralph Thurman previously served as the chairman and CEO of VIASYS Healthcare, Inc., a publicly traded private equity medical technology firm that he founded in 1999. He increased its value fourfold over eight years and sold it for 14.3 times its earnings before interest, taxes, depreciation, and amortization (EBITDA) in 2007. Before he launched VIASYS Healthcare, he served for five years as the board chairman and CEO of Corning Life Sciences, where he expanded global sales from $700 million to in excess of $2 billion.
Ralph Thurman began his career at Rhone-Poulenc Rorer Pharmaceuticals, Inc., and eventually became the president during his nine-year tenure with the company. Prior to this, he was a US Air Force fighter pilot and an instructor for an Air Force advanced fighter pilot training program. An alumnus of the Wharton School at the University of Pennsylvania’s corporate governance program, he has a master of arts in management and an undergraduate in economics from Webster University and Virginia Polytechnic Institute and State University, respectively.